We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Cell Line Engineering Makes Well-characterized Antibody More Accessible

News   Aug 01, 2018 | Original story sourced from the US National Institute of Standards and Technology

 
New Cell Lines Produce an Antibody Key for Biologic Drug Production

HeLa cancer cells appear green wherever mouse monoclonal antibodies (mAb) have bound to tubulin, a structural protein important in cell division. Binding to tubulin and preventing cell growth is one way that mAb drugs could kill tumors -- the type of research that may benefit from the use of NIST's monoclonal antibody reference material, NISTmAb. Credit: ©EnCor Biotechnology Inc.

 
 
Advertisement
 

RELATED ARTICLES

How Uromodulin Helps Against Urinary Tract Infections

News

The exact process by which uromodulin prevents inflammation had never been understood. Now an interdisciplinary team, drawn from three research groups at ETH Zurich together with researchers from the University of Zurich and the Children's Hospital Zurich, has filled this knowledge gap.

READ MORE

Accelerated Discovery of Bioactive Components in Seaweed

News

Using state-of-the-art approaches coupled with bio- and cheminformatics and machine learning, researchers at the GEOMAR Helmholtz Centre for Ocean Research Kiel have succeeded in discovering new, bioactive components of the Baltic Sea seaweed Fucus vesiculosus and its fungal symbiont against infectious bacteria or skin cancer.

READ MORE

Hydroxychloroquine and Lopinavir/Ritonavir Treatment Arms for COVID-19 Discontinued

News

the World Health Organization (WHO) has accepted the recommendation from the Solidarity Trial’s International Steering Committee to discontinue hydroxychloroquine and lopinavir/ritonavir study arms.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE